Background: Immunotherapy of patients suffering from the human epidermal growth factor receptor 2 overexpressing\n(HER-2+) breast cancers with the anti-HER-2 antibodies results in increase of the patientsââ?¬â?¢ overall survival.\nHowever, no prophylactic vaccine is available against HER-2+ breast cancers. Although, prophylactic vaccine for\nhuman hepatitis B virus (HBV) is very effective.\nSpecific aim: The specific aim of this work was to design, synthesize, and test bio-molecules which would engage\nprophylactic immunity against hepatitis B virus towards killing breast cancers cells.\nMethods and Results: By biomolecular engineering, we have created a novel family of biomolecules: antibody\n(anti-HER-2) Ã?â?? vaccine (HBsAg) engineered constructs (AVEC: anti-HER-2 Ã?â?? HBsAg). These biomolecules were utilized\nfor redirecting, accelerating, and amplifying of the vaccination-induced, prophylactic immunity originally targeted\nagainst HBV as therapeutic immunity, newly targeted against HER-2+ breast cancers. Treatment of the HER-2+ breast\ncancer cells with AVEC: anti-HER-2 Ã?â?? HBsAg in blood of the patients, vaccinated with HBsAg, rapidly increased efficacy\nof killing of HER-2+ breast cancer cells over that attained with the naked anti-HER-2 antibodies.\nConclusion: Novel antibody-vaccine engineered constructs (AVEC) facilitate redirecting, accelerating, and amplifying\nof prophylactic, HBV vaccination-induced immunity as immunotherapy (RAAVIIT) of HER-2+ breast cancer. We currently\nstreamline this novel therapeutic paradigm into clinical trials of breast and other cancers.
Loading....